Home / Metal News / Dongguang: net profit of 1.11 billion yuan in 2019 up 2.01% from the same period last year

Dongguang: net profit of 1.11 billion yuan in 2019 up 2.01% from the same period last year

iconApr 3, 2020 15:17
Source:SMM

SMM: on April 3, Dongguang's latest 2019 annual report showed that the company realized 14767210574.93 yuan in operating income, an increase of 26.43% over the same period last year, 2411880005.48 yuan in total profit, an increase of 34.53% over the same period last year, and 1112477114.65 yuan in net profit belonging to the owner of the parent company, an increase of 2.01% over the same period last year.

During the reporting period, the company's main business revenue mainly came from industrial production and processing business, among which: the contribution rate of the new electronic material industry to the main business income was 20.79%, the contribution rate of the alloy material industry to the main business income was 23.13%, the contribution rate of the chemical products industry to the main business income was 11.93%, and the contribution rate of the pharmaceutical industry to the main business income was 42.77%.

The global economy is in a downward trend, and the impact of the continuing trade war between China and the United States has gradually spread to all walks of life in China. Affected by the reduction of export orders and the cyclical impact of the chemical industry, the company has experienced varying degrees of decline in the volume and price of electrode foil and chemical products. However, with the advantages of a complete industrial chain and R & D platform, the company continues to improve product technology and strictly control costs, and actively adjust the production structure of products. By increasing the expansion of R & D, production and sales channels for pharmaceutical products, the overall sales of the company continued to grow during the reporting period, and its main business income increased by 27.63% over the same period last year, especially pharmaceutical products. Due to the remarkable results of academic promotion and channel subsidence, the company's leading pharmaceutical products Kewei drug sales increased significantly, and the main business income of pharmaceutical products increased by 155.41% compared with the previous year.

During the reporting period, the company gradually promoted the expansion project in accordance with the development strategy and business plan. Among them, the company in the Wulanchabu layout of the medium and high pressure foil expansion project, the first phase of the foil production line main plant and supporting facilities have been completed, the first 24 foil production lines have been formally put into production, the new medium and high voltage foil production capacity of 7 million square meters, the production line has been identified by Japan Rubycon, NIPPOM CHEMI-COM, Nichicon, South Korea Sanhe and other major customers site, ready for the sale of follow-up products, with the release of future production capacity, Relying on local power preferential policies will help to reduce the company's production costs and improve the company's market competitiveness. The brazing foil expansion project and battery foil project cooperated with UACJ Co., Ltd. are progressing smoothly. Some equipment is expected to be put into production in 2020, with an additional capacity of 40, 000 tons. The project mainly applies Japan's high-end battery foil production technology, and its core customers include Panasonic, Japan and other international top battery manufacturers to replace Japanese imports.

"Click to sign up:" 2020 (15th) China International Aluminum processing Summit "

Scan QR codes, apply to attend the meeting or join the SMM Metal AC Group

East Sunshine
Aluminum foil
Alloy

For queries, please contact Michael Jiang at michaeljiang@smm.cn

For more information on how to access our research reports, please email service.en@smm.cn